McKesson Corporation vs Prudential PLC — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: McKesson Corporation is far larger — about 3.8× Prudential PLC's market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Prudential PLC for 119 Days on average.
| MCK | PUK | |
|---|---|---|
Market Cap | $108.46B | $28.84B |
Volume | 712,607 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $995.69 | $33.61 |
52-Week Low | $725.17 | $23.54 |
Typical Hold Time | 74 Days | 119 Days |
Enterprise Value | $115.00B | $28.38B |
Dividend Yield | 0.4% | 2.33% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
PUK trades at $23.88, up 1.44% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company demonstrates strong fundamentals with $27.4B revenue, 14.52% net margin, and attractive valuation at 8.4 P/E ratio. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while maintaining consistent dividend payments.
PUK presents a value opportunity with solid profitability and growth trajectory, though near-term technical weakness and emerging market exit execution risks require monitoring. Analyst consensus leans positive with 50% buy ratings, supporting potential upside from current levels if operational improvements materialize as planned.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →